---
title: "Eton Pharmaceuticals Chief Business Officer Sold Shares Worth Over $3.2M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287828470.md"
description: "David Krempa, Chief Business Officer of Eton Pharmaceuticals, sold shares worth $3.2 million, with transactions executed at prices between $31.47 and $33.88 per share. The sales occurred on May 22, 26, and 27, 2026, totaling $3,229,923. Post-sale, Krempa retains 25,249 shares of common stock."
datetime: "2026-05-27T22:30:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287828470.md)
  - [en](https://longbridge.com/en/news/287828470.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287828470.md)
---

# Eton Pharmaceuticals Chief Business Officer Sold Shares Worth Over $3.2M

David Krempa, an officer serving as Chief Business Officer, filed a Form 4 reporting sales of Eton Pharmaceuticals common stock. The transactions were executed at weighted-average prices ranging roughly from $31.47 to $33.88 per share as reported and in multiple trades at specified price ranges. The total proceeds from the five sales reported on May 22, May 26 and May 27, 2026 amounted to $3,229,923. After these transactions, Krempa directly beneficially owns 25,249 shares of common stock. The reporting person authorized a designated filer to submit this Form 4 on his behalf.

Reporter Name

Krempa David

Relationship

Chief Business Officer

Type

Sell

Amount

$3,229,923

SEC Filing

Form 4

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ETON.US](https://longbridge.com/en/quote/ETON.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)

## Related News & Research

- [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md)
- [Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO](https://longbridge.com/en/news/287025596.md)
- [Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700 | ETON Stock News](https://longbridge.com/en/news/284199494.md)
- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)
- [Eton Pharmaceuticals (ETON) Expected to Announce Earnings on Thursday](https://longbridge.com/en/news/278822789.md)